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 Abstract 
Background 
In colorectal and breast cancer, the density and localization of immune infiltrates provides 
strong prognostic information. We asked whether similar automated quantitation and combined 
analysis of immune infiltrates could refine prognostic information in high-grade serous ovarian 
carcinoma (HGSOC) and tested associations between patterns of immune response and genomic 
driver alterations. 
Methods 
Epithelium and stroma were semi-automatically segmented and the infiltration of CD45RO​+ ​, 
CD8​+​ and CD68​+​ cells was automatically quantified from images of 332 HGSOC patient tissue 
microarray cores.  
Results 
Epithelial CD8 (p=0.027, HR=0.83), stromal CD68 (p=3​×​10-4, HR=0.44) and stromal CD45RO 
(p=7​x​10​-4​, HR=0.76) were positively associated with survival and remained so when averaged 
across the tumour and stromal compartments. 
Using principal component analysis, we identified optimized multiparameter survival models 
combining information from all immune markers (p=0.016, HR=0.88). There was no significant 
association between PTEN expression, type of ​TP53​ mutation or presence of ​BRCA1/BRCA2 
mutations and immune infiltrate densities or principal components. 
Conclusions 
Combining measures of immune infiltration provided improved survival modeling and evidence 
for the multiple effects of different immune factors on survival. The presence of stromal CD68​+ 
and CD45RO​+​ populations was associated with survival, underscoring the benefits evaluating 
stromal immune populations may bring for prognostic immunoscores in HGSOC. 
Introduction  
There is a heterogeneous immune response in the tumour microenvironment of HGSOC, but the 
presence of intra-epithelial CD8​+​ T-cells is consistently associated with improved survival​1,2 ​. 
Prolonged survival is also associated with the presence of B cells and other immune cells, 
including CD45RO​+​memory cells​3-6​.  
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Prognostic scoring has predominantly focused on the presence, absence or semi-quantitative 
analysis of immune cells in tumour epithelium​7​. Moreover, cell densities of lymphocytes, 
macrophages and dendritic cells have also been shown to be prognostic in breast, ovarian and 
lung cancer without restricting analyses to malignant epithelial cell areas​8-10​. Approaches that 
combine analyses of multiple immune infiltrates, such as the CD3/CD8 immunoscore in 
colorectal cancer​11​, have not yet been developed for ovarian cancer prognosis.  
The notion that anti-tumoural immune responses may be altered by tumour cell-intrinsic factors 
is supported by several observations. Detailed temporal and spatial histological and genomic 
studies in a single patient with high grade serous ovarian carcinoma (HGSOC) showed Wnt 
signalling was upregulated in a progressing tumour nodule, a phenomenon correlated with focal 
immunosuppression​12​. Mutations in the ​TP53​ and ​BRCA1​/​BRCA2​ genes as well as loss of ​PTEN 
expression are driver events in HGSOC development​13 ​. HGSOC cases with ​BRCA1 ​mutations have 
increased CD8 and CD20 intra-epithelial infiltrates​14,15​ suggesting that loss of homologous 
recombination and DNA damage may prime immune responses. Whether different classes of 
TP53 ​mutations alter immune infiltration in HGSOC remains unknown but non-synonymous 
mutations in ​TP53 ​may have gain-of-function or other cellular effects distinct from 
loss-of-function mutations​16​. Mutant p53 protein may drive B cell responses and autoantibody 
production​17​. Loss of ​PTEN ​expression in melanoma was associated with both reduced T-cell 
infiltration and resistance to immune checkpoint inhibitors​18​, but these associations have not 
been investigated in HGSOC. 
Despite the strong association of CD8​+​ infiltrate with prognosis, routine immunoscoring for 
ovarian cancer is not performed in the clinic and development of automatic cellular recognition 
tools could be beneficial for high throughput pathology workflows.  To test the hypothesis that a 
more integrated analysis of cytotoxic, mature and organised immune responses in the tumour 
microenvironment might have greater prognostic value in HGSOC, we developed new image 
analysis methods and workflows to test the single and integrated analysis of CD8​+​, CD45RO​+​ and 
CD68​+​ in the malignant epithelium and adjacent stroma. The secondary aim of this study was to 
test for association between quantitative measures of CD8​+ ​, CD45RO​+ ​ and CD68​+ ​ cells and driver 
genomic alterations in ​BRCA1​, ​BRCA2​, ​PTEN ​and different classes of ​TP53 ​mutation. 
Materials and methods 
Patients 
Samples from 570 patients from the prospective SEARCH ovarian cancer population-based 
study were used to construct tissue microarrays​19​. Ethical approval was granted by the Eastern 
Multicenter Research Ethics Committee. Among the samples from 570 patients with primary 
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epithelial ovarian tumours, 332 were high grade serous ovarian cancer patients. All cases 
underwent detailed histopathological review by a gynaecological pathologist (JM). Patients were 
staged as having localized, regional or distant disease (L/R/D)​20 ​. 
Immunohistochemistry 
Microarray slides composed of FFPE embedded ovarian tumour cores were dewaxed and 
rehydrated prior to heat induced epitope retrieval (HIER) using a pressure cooker and a 
citrate-based antigen unmasking solution (Vector Laboratory). Detection of CD8​+ ​ T cells, 
CD45RO​+​ memory lymphocytes and CD68​+​ macrophages was performed using the mouse 
anti-human CD8 (Clone C8/144B, Dako), mouse anti-human CD45RO (Clone UCLH, Dako) and 
mouse anti-human CD68 (Clone M0876, Dako) antibodies, using ultrasensitive Polymer-HRP 
IHC Detection system (Biogenex). Immunohistochemical protocols and slide hybridizations 
were carried out manually. Sections were counterstained with haematoxylin and mounted with 
DPX mounting medium (Sigma). Previously published PTEN immunostaining data was used 
where high PTEN expression was considered to be positive staining and low expression to be 
weak, heterogeneous or negative staining respectively​21​. 
Mutation analysis 
The coding regions of ​TP53 ​were sequenced by tagged-amplicon next generation sequencing as 
previously described​22​ and confirmed by immunohistochemical analysis using a 4-tier core 
system​23​. Sequencing of germline mutations in the ​BRCA1 ​and ​BRCA2 ​genes was performed as 
previously described​24​. 
Immune cell quantification 
Stained slides were scanned using the Panoramic Slash Scanner (3D Histech). The number of 
CD8​+​ and CD45RO​+​ cells per mm​2​ of epithelial and stroma areas, as well as the percentage of 
epithelial and stromal areas covered by CD68 staining, were digitally determined using the 
Tissue Studio software (Definiens™). Definiens image analysis algorithms for detection of 
epithelial and stromal areas were trained and the segmentation for each core was manually 
refined by two researchers including a consultant gynaecological-histopathologist (J. McD.). 
Supplementary Figure 1 shows examples of classifications of tissue regions and cell detection 
and the entire data set, including these epithelial and stromal assignments, can be downloaded 
from the repository. 
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Statistical analyses 
R (version 3.5.1) was used for statistical analysis and an R markdown document containing the 
entire data set allowing for performing all analyses is available 
(https://bitbucket.org/jamesdbrenton/search-montfort/src/master/). Quality checking for 
spatial bias across TMAs and effects of varying tissue area was carried out upon all cores and 
across TMAs using heatmaps and Shapiro-Wilk tests. All count data were transformed to log 
base 10 after adding a small offset to zero values. Wilcoxon signed rank test was used to 
compare the mean infiltrate between groups. Continuous data were presented as median and 
interquartile range (IQR) and groups were compared by the Kruskal–Wallis and pairwise 
Kruskal-Wallis tests. Discrete data were presented as count and percentage.  
Cox proportional hazard regression analysis was applied to assess the effect of each infiltrate on 
overall survival. The functional form of each of the immune variables was assessed using 
comparison with cubic splines. The best approximations to the functional forms were carried 
forward for the Cox models.  The clinical variables of age at diagnosis, menopause status and 
stage were available for the cohort and were included in the analysis. Univariable Cox 
regressions were used to identify best-fitting variables for the final multivariable Cox regression 
model. The refined model was compared with a combined multivariable Cox regression model 
including all immune infiltrates. Hazard ratios (HR) refer to a single unit increase in continuous 
variables. The proportional hazards assumption was tested and satisfied in all cases using 
Schoenfeld residuals. The Kaplan–Meier analysis (with log-rank test) was applied to illustrate 
survival differences graphically. Two-sided P-values <0.05 were used to indicate statistical 
significance.  
Principal component analysis (PCA) using the R package prcomp was used to extract the 
independent components of variance between patients. The package prcomp uses singular value 
decomposition and the variables were scaled to have unit variance before creating composite 
linear independent variables. These were then passed forward to the survival modelling. The 
Akaike Information Criterion (AIC) was used to compare the performance of survival models, 
which includes a penalty on the number of terms to reduce overfitting. Bonferroni p-value 
corrections were carried out for all multiple testing. P < 0.05 was considered significant for all 
analyses.  
Results 
Patient characteristics 
Supplementary Fig. 2 shows the REMARK diagram for this study and Supplementary Table 1 
shows the clinical characteristics of the 332 HGSOC patients from the study cohort. 
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Immunohistochemical analyses on tissue microarrays (TMAs) were performed to detect CD8​+​, 
CD45RO​+​ and CD68​+​ cells in tissue cores from primary ovarian specimens.  152 HGSOC cases 
were available for analysis after quality assurance, data cleaning and the reduction of the data 
set to only cases with complete results for CD8, CD45RO and CD68 staining in both epithelium 
and stroma as well as survival data.  
Tagged amplicon sequencing was performed on 248 cases and ​TP53 ​mutation was detected in 
231 samples (93%) (Supplementary Table 1). Previously published data for germline ​BRCA1 
and ​BRCA2 ​mutation and PTEN expression were available for 297 and 155 cases 
respectively​18,22​. 
Digital pathology analysis of tumour composition and immune cell densities 
Image analysis software was used to determine the area of tumour epithelium and stroma in 
each core (Fig. 1 and Supplementary Fig 1). Of 964 images representing 332 HGSOC patients, 69 
patients (20.8%) had images which contained malignant epithelium but no stroma; 250 patients 
(75.3%) had images which contained epithelium and >1% adjacent stroma and 13 patients 
(3.9%) had images containing no tumour epithelium (Fig 1 A). The median proportion of 
epithelium and stroma was 85.1% (IQR 51–100%) and 14.9% (IQR 0–49%) respectively. We 
expected the proportion of tumour in a sample to be correlated with p53 mutant allele fraction, 
a measure of sample purity, and found them to be positively correlated (R​2​= 0.25, p=0.0004). 
Quantitative densities of all immune populations were then generated automatically through 
image analysis, the quantitative assessment of CD8​+​ T cell, CD45RO​+​ memory lymphocyte and 
CD68​+​ macrophage densities in each compartment are shown in Supplementary Fig. 1. The 
relationship between the fraction of tumour in a core and the density of immune infiltration in 
the epithelium was examined. Intra-epithelial CD8​+ ​ and CD45RO​+ ​ densities were weakly 
correlated with the purity/tumour fraction of the sample (R​2 ​ = 0.17, p = 0.003 and R​2​ = 0.16, 
p=0.006) but CD68​+​ epithelial density was not. 
The three immune populations in our samples showed moderate to strong correlation between 
epithelium and stroma (Supplementary Fig. 3 and Supplementary Table 2). Samples with low 
density of stromal immune populations generally had low density of epithelial infiltrate and vice 
versa. The distribution of densities of immune populations within tumour epithelium and 
stromal areas were compared (Fig. 1B–D). The density of CD8​+​ and CD45RO​+ ​cells were 
significantly higher in stroma than tumour epithelium (p = 0.005 and p = 0.004 respectively; 
Welch’s t-test) but not significantly different for CD68​+​ cells. 
In describing the patterns of immune infiltrate, the terms immune-inflamed, immune-desert and 
immune-excluded have been used to describe varying T-cell infiltration based on histological 
and transcriptional analyses​12,25-27​. Immune-inflamed and immune-desert patterns reflect high 
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positive or negative correlations between all infiltrates but T-cell exclusion describes tumours 
where CD8​+​ cells are significantly absent from tumour epithelium whilst still being present in 
the surrounding stroma​28,29​. Given the higher infiltration in stroma than epithelial 
compartments, we defined immune cell exclusion as a 10-fold difference between tumour 
epithelium and stromal infiltration as the standard deviation of the log10 transformed counts 
was approximately 1. CD8​+​ exclusion was present in 20 (10.6%) cases and 36 (20%) cases had 
CD45RO​+​ exclusion. No cases had significant exclusion of CD68​+​ infiltrate from tumour 
epithelium.  Notably none of the cases had both CD8​+​ and CD45RO​ + ​ exclusion.  
Stromal CD68​+​ and CD45RO​+​ densities are the strongest individual prognostic markers 
Survival was modelled using Cox proportional hazards and the relationship between the 
immune variables and survival was found to be approximately log-linear. The clinical variables 
accompanying the cohort were age at diagnosis, stage and menopause status and the 
relationship between age and survival was found to be approximately linear (See Methods, 
Supplementary Figure 4, Supplementary Table 3).  
Univariable analysis showed improved survival with increasing stromal density of CD45RO​+​ (HR 
0.76 95% CI 0.65–0.90, p=0.001) and CD68​+ ​(HR 0.53 95% CI 0.34–0.81, p=0.003) (Table 1). 
Modelling each immune variable with stage showed improved predictive value for epithelial 
CD8​+​ density (HR=0.83, p-value=0.027) as well as stromal CD68​+​ and CD45RO​+​ density and 
epithelial CD45RO​+​ density (Table 1). Figure 2 and Supplementary Figure 5 shows illustrative 
Kaplan-Meier survival curves for high and low stromal and epithelial CD68​+ ​, CD45RO​+ ​and CD8​+ 
densities.  
In cores with <1% stroma, epithelial CD8​+ ​ malignant epithelial infiltrate remained an 
independent prognostic factor but epithelial CD45RO​+ ​ density was not significant 
(Supplementary Table 4). 
In clinical reporting, quantifying immune populations in exclusively tumour epithelium is 
technically challenging and time consuming. We tested the effects of using the average density of 
each marker averaged across both tumour and stromal regions from each core (Table 1). 
Averaging the tissue density of CD8​+​ increased the strength of the associated hazard ratio and 
significance of the model (HR=0.79, p-value=0.010) indicating increased prognostic value over 
quantitation of individual epithelial and stromal infiltrates. Supplementary Figure 5 shows 
illustrative Kaplan-Meier survival curves for high and low CD68​+ ​, CD45RO​+ ​and CD8​+ ​ densities 
over combined epithelium and stroma compartments. 
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Multivariable Cox regression analysis including all infiltrates and stage was carried out on 
patients with complete data for all infiltrates (n=152) (Table 2).  In this model only stage and 
CD68​+​ stromal infiltrate were significant predictors of survival.  
We then refined the model by removing the least significant elements (defined as those with 
p>0.1) (Table 2, n=152). Interestingly, we found that the p-values for CD68​+ ​ and CD45RO​+ 
stromal infiltrates in the refined model become less significant and the hazard ratios are 
attenuated in comparison to both the univariable regression and the full model. This is likely 
due to the inability of Cox regression to distinguish with confidence whether stromal CD45RO​+ 
or CD68​+​ density is the most significant predictor when there is a strong correlation between all 
the immune variables. 
Principal components of the combined immunospace describe biologically interpretable 
effects. 
 As the three types of immune infiltrate vary continuously across epithelium and stroma these 
variables can be regarded as six dimensions of an ‘immunospace’ (three infiltrates, 2 
localizations).  Given the strong correlations between infiltrates (Supplementary Figure 3), these 
immune variables are not independent. We used principal component analysis (PCA) to 
determine the independent patterns across these dimensions, using the 152 patients for whom 
complete data were available. PCA transformed the six correlated infiltrate variables into six 
independent axes with the first component containing the largest proportion of variance (60%) 
in the data set (Supplementary Table 5). 
In principal component 1 (PC1), the weightings of all immune infiltrates are positive and similar 
in magnitude (Supplementary Table 5). This indicates that as one infiltrate increases so do all 
the others and represents the degree of coordinated immune response. The remaining principal 
components characterize additional patterns across immune infiltrates independent of PC1. The 
additive contribution of PC2 characterises negative correlation between CD8​+ ​ infiltrates and 
CD68​+​ macrophages and CD45RO​+​ memory cells. PC3 characterizes additional variation where 
epithelial and stromal infiltrates are negatively correlated, the most positive values of PC3 
correspond to high infiltration in tumour epithelium compared to stroma and the most negative 
values of PC3 correspond to the opposite, the aforementioned immune exclusion.  
Supplementary Fig. 6 shows representative images with the largest magnitudes of PC1, PC2 and 
PC3 to visually illustrate the patterns described above. The variance in the remaining principal 
components (4-6) is smaller and less informative. Variance in PC4 is predominantly from 
CD45RO​+​ stromal density, PC5 is from CD45RO​+​ epithelial density and PC6 is from CD68​+ 
epithelial density. Patients are plotted by their PC1 and PC2 values in Supplementary Fig. 7.  Cox 
proportional hazard regression was used to assess whether these principal components were 
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predictive of survival. Only PC1 was an independent predictor of survival in our cohort and was 
associated with improved survival (Univariate: HR=0.89, p-value=0.024, PC1+Stage: HR: 0.88, 
p-value=0.019) (Supplementary Table 6) reflecting the good prognosis of a strong coordinated 
immune response. The association of this principal component with survival is also illustrated 
graphically using Kaplan Meier curves in Fig. 3. 
Cox regression survival models were also calculated on all combinations of principal 
components and stage. The Akaike Information Criterion (AIC) was used to compare the 
performance of these survival models and includes a penalty on the number of terms to reduce 
overfitting (Supplementary Fig. 8). The model combining stage, PC1 and PC5 had the best 
performance for predicting overall survival. The improvement with the addition of PC5 shows 
that the addition of this principal component has a suppressor effect in the model, increasing the 
significance of other variables when included. This demonstrates that survival is predominantly 
determined by the coordinated immune response and further variation in survival from this 
trend can be encoded by the quantity of epithelial CD45RO​+ ​ infiltrate. Interestingly, the models 
that contained stage and either stromal CD45RO​+​ or CD68​+ ​ infiltrate contained a similar amount 
of information about patient survival as the one that contained stage and principal components 
1 and 5. In our cohort, the density of CD68​+​ and CD45RO​+ ​ stromal infiltrates are therefore the 
best single infiltrates for survival modelling.  
Are genetic defects associated with HGSOC driving individual infiltrates or the 
coordinated immune response in tumours? 
The presence of germline ​BRCA2​ mutations was significantly associated with lower CD8​+​ cell 
density than patients with a ​BRCA1​ after multiple testing correction (Table 3). There was no 
significant association between the quantity of CD45RO​+ ​ or CD68​+​ infiltrate and the mutational 
status of either ​BRCA1 ​or ​BRCA2 ​genes (Table 3). No significant association was detected 
between ​TP53 ​GOF and LOF mutations or PTEN expression and the densities of CD8​+ ​, CD45RO​+ 
and CD68​+​ cells in epithelium or stroma (Table 3). Similarly, changes in the principal 
components were not significantly associated with PTEN expression, ​TP53 ​GOF or LOF mutation 
or germline ​BRCA1​/​BRCA2​ mutation status (Table 3). 
Discussion 
Infiltration of immune cells in HGSOC tumours has previously been correlated to prognosis for 
patients​1,30​. However, translation of these tools to the clinic has been impeded by the lack of 
standardised and reliable quantitation methods. In this work, we used a semi-automated 
approach to quantify the CD8​+​, CD45RO​+​ and CD68​+​ infiltrates in both stromal and epithelial 
areas of primary HGSOC tumours. We found that immune infiltration in the tumour 
microenvironment was continuously distributed across a wide range and CD8​+​, CD45RO​+ ​ and 
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CD68​+​ infiltrates were strongly correlated. T-cell exclusion from epithelial regions has been 
previously reported​29​. We only observed epithelial exclusion of CD8​+ ​ or CD45RO​+​ in 10% and 
20% of patients, respectively. These groups were mutually exclusive, suggesting that immune 
exclusion from epithelial or stromal regions, is a tumour-specific effect that is distinct from 
coordinated multi-infiltrate immune responses. 
Our results for the positive prognostic effects of epithelial CD8​+ T cells are consistent with the                
large study by Goode et al, who described a near log-linear relationship between the density of                
epithelial CD8​+ T cells and survival​2​. However, our observations also show that averaging CD8              
density across the total core (epithelial and stromal areas) improves survival prediction. The             
alternative possibility that epithelial and stroma compartments have been misassigned is highly            
unlikely as these assignments were all reviewed by a gynaecological pathologist. The            
combination of both stroma and tumour epithelium potentially provides a better representation            
of the dynamics of epithelial infiltration by including cells that may be poised to infiltrate. 
CD45RO is a memory marker for T cells and B cells. In the tumour microenvironment, we and                 
others​5,31,32 have shown that CD4​+ ​and CD8​+ T cells, myeloid cells and B cells are mainly located                 
in the stroma of tumours whereas CD8​+ T cells can be found in both areas. Meta-analyses                
investigating the prevalence of CD45RO in solid cancers reported high CD45RO infiltrate was             
associated with better prognosis for patients​33 ​. We confirmed these results in HGSOC and             
demonstrated that the quantity of stromal and average densities of CD45RO​+ cells over the              
whole core are prognostic. We also demonstrated that epithelial CD45RO​+ density was a             
significant predictor of survival in cores with >1% stroma but not in those with <1% stroma.                
This result emphasises the need to contextualise epithelial infiltrate and the confounding nature             
of tumour composition on survival impact. 
The link between tumour infiltration with macrophages and patient survival is more complex. 
Previous studies demonstrated the positive predictive value of classically activated (M1) over 
tumour-promoting (M2) macrophages in ovarian cancer​9,34​. However, no significant association 
was found between the level of intra-epithelial CD68 infiltrate and patient survival​4​. Our study 
confirms this latter result and also demonstrates a significant association between a high 
coverage of stromal areas with CD68​+​ macrophages and improved overall survival. This result is 
in line with a recent study showing a high infiltration of CD68​+ ​ macrophages at the invasive 
front of tumour sections from colorectal cancer patients is correlated to better response to 
chemotherapy​35​. Whereas tumour-associated macrophages (TAM) promote cancer progression 
via stimulation of multiple processes including angiogenesis, inflammation and immune escape, 
it now appears evident that the phenotype of TAM changes in different areas of the tumour​36,37​. 
Taking into account the seemingly contradictory results obtained on this subject, additional 
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studies aiming at deciphering the precise role distinct subpopulations of macrophages 
infiltrating different areas of tumours play in cancer progression is required. 
All three infiltrates were also found to be predictive in multivariate analyses adjusted for 
tumour stage. We previously demonstrated that optimal response to neoadjuvant chemotherapy 
was significantly associated with a decrease in the density of FoxP3​+ ​ regulatory T cells in the 
stroma of human HGSOC tumours​38​. As we did not have access to treatment information for 
patients included in this cohort, we cannot rule it out as a potential confounding factor.  
Importantly, we show that combining our six correlated types of immune infiltrates using             
principal component analysis allowed us to transform inter-patient variations of the tumour            
immune landscape into independent, biologically interpretable principal components. We find          
that the main source of variation between patients is reflective of the quantity of concerted               
immune response. The second principal component demonstrates that there is a pattern of             
significant variations in the CD8​+ infiltrate of some patients that is independent and acting in               
opposition to the concerted immune response. The third principal component measures the            
extent of negatively correlated epithelial and stromal infiltrates and is weighted differently by             
infiltrates. This supports our observation that immune exclusion is common, variable by            
infiltrate and shows that this is an additional effect to that of the concerted immune response.  
The main limitation of our analysis of the “immunospace” and its principal components is that 
we could only apply it to images that contain both epithelium and stroma. This reduced the size 
of the cohort we could analyse. With foresight, sampling could be designed to include both 
regions in TMAs and sectioning and imputation could be carried out for missing data. It is worth 
noting that being able to combine multiple correlated infiltrates and elucidate patterns and 
sources of variation will become even more important as many more (30+) immune markers 
are combined on single sections using imaging methods such as Hyperion. This method is 
particularly useful in that it also allows us to measure the strength of immune patterns 
occurring across multiple infiltrates. Analysing principal components also avoids some 
statistical issues that are associated with frequent co-correlation between different immune 
populations. Including correlated variables in a typical multivariable Cox regression survival 
model not only reduces interpretability but can also cause model results to be variable under 
bootstrapping as seen in the refined model of our cohort. 
We found that the first principal component was independently associated with survival. This 
result is consistent with a previous study showing that the simultaneous infiltration of tumours 
by different subsets of leukocytes (e.g. T cells, plasma cells, B cells), likely reflecting the 
establishment of a concerted immune response, gives a survival advantage to ovarian cancer 
patients​5​. We used the principal components to model survival and found that a model including 
PC1 and PC5 was as predictive as individually modelled stromal CD45RO and CD68 infiltrates. 
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Therefore, CD68 or CD45RO markers analysed in epithelium-adjacent stroma constitute the best 
single prognostic markers in our cohort. 
In human lung adenocarcinoma, Mansuet-Lupo et al showed that oncogenic mutations in the 
TP53 ​gene were positively correlated with CD8​+​ infiltrate​39​. In their study, intra-epithelial CD8​+ 
T cell numbers and ​TP53 ​status were both linked to prognosis with patients harbouring 
tumours with low CD8​+​ infiltrate and non-disruptive ​TP53​ mutation (associated with 
gain-of-function) being linked to poorer survival. In glioblastoma, ​TP53 ​mutations were also 
associated with increased immune infiltrate​40 ​. In the present work, we integrated histological 
and genomic features to evaluate whether genetic alterations could be linked to different 
quantities of immune infiltration. We found no correlation between the nature of ​TP53 
mutations and the amount of CD8​+​ T cells, CD45RO​+ ​memory lymphocytes and CD68​+ 
macrophages in the stromal and malignant areas of 197 HGSOC tumours or the values of the 
principal components we derived. Overall, the exact nature of the relationship between 
subtypes of ​TP53​ mutations and immune infiltrate is still unclear and likely to vary across 
different cancers, as evidenced by two studies showing ​TP53 ​GOF mutations to be associated 
with pro-tumour effects related to inflammation in glioblastoma​40 ​ and immunosuppression in 
lung adenocarcinoma​41​. 
PTEN, another essential tumour suppressor, regulates the production of immunosuppressive 
cytokines by melanoma cells​42​. In human melanoma, ​PTEN​ deletion was correlated with a 
decrease in infiltrating CD8​+ ​T cells​18​. In HGSOC however, we observed no correlation between 
the expression level of PTEN and the number and/or localisation of CD8​+ ​, CD45RO​+ ​and CD68​+ 
leukocytes in the tumour microenvironment or the principal components we derived. The 
discrepancy between the results obtained with HGSOC and melanoma tumours might lie in the 
fact that in our study loss of PTEN expression was only partial with tumours divided into 
expressing high or low levels of PTEN.  
In contradiction to a previous work​43​, we did not observe a significant correlation between the 
number of intra-epithelial CD8​+​ T cells and mutations in the ​BRCA1 ​gene.  As there were only 18 
patients with a ​BRCA1 ​mutation in this cohort, this is most likely related to a broad confidence 
interval as compared with the null population. We did however find a significant difference in 
intra-epithelial CD8​+​ T cell infiltration between ​BRCA1 ​and ​BRCA2 ​patients, with ​BRCA1 ​patients 
having significantly higher infiltration than ​BRCA2​. The discrepancy could also be linked to the 
automated and continuous quantitation method used in our study to quantify the immune 
infiltrate of tumours, as scoring in the previous study was done manually and in a stratified 
manner​43​. Furthermore, we did not assess the methylation in the gene coding region for ​BRCA1 
and restricted our analysis to the identification of germline mutations in the​ BRCA1​ and ​BRCA2 
genes.  
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Our work shows that averaging immune infiltration over the whole tissue core could be as 
useful as current methods and potentially provides more prognostic information. Methods that 
average counts of immune cells across tissues are also simpler to implement than 
epithelial:stromal segmentation methods. Nonetheless, careful sampling of the tumour 
microenvironment with inclusion of both epithelium and stroma remains very important as 
both areas have independent prognostic significance.  
Our results showing strong positive prognostic significance of stromal CD68​+ ​infiltrate in HGSOC 
tumours warrants further investigation into the role and properties of CD68​+ ​ macrophages in 
HGSOC and also may caution against the use of new potential macrophage-depleting therapies. 
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Figure Legends: 
Figure 1. Proportions of immune cells vary between epithelial and stroma areas of 
tumours. (A) Scatter plot of the average stroma and epithelial tumour areas for each 
patient.​ (B), (C) and (D) show respectively the distribution of densities of CD8​+​, CD45RO​+​ and 
CD68​+​ cell in epithelium and stroma. CD8​+​ and CD45RO​+​ densities were defined as counts per 
mm​2 ​and CD68​+​ as the percentage of tissue stained for this marker. (Notches on box plots extend 
1.58 ​✕​ IQR / sqrt(n) and approximate the 95% confidence interval for the median. Box plot 
whiskers extend to 1.5 ​✕​ IQR.)  
Figure 2. Survival analysis of HGSOC patients relative to the density of CD68​+ 
macrophages and CD45RO​+​ cells in their stroma. ​Kaplan–Meier survival curves using cut 
point of median density of stromal CD68​+​ macrophages and CD45RO​+ ​ memory T cells using left 
17 
truncation and right censoring. Median entry to the study for all patients after diagnosis was 
26.4 months. Median follow up time from diagnosis to exit or death was 105.1 months.  
Figure 3. Survival analysis by principal component 1 (PC1).​ Kaplan–Meier analysis using 
median cut point for PC1 with left truncation for study entry variables and right censored at 120 
months. Median entry to the study for all patients after diagnosis was 26.4 months. Median 
follow up time from diagnosis to exit or death was 105.1 months.  
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Table	1.	Hazard	ratios	from	the	Cox	proportional	model	for	all	infiltrates	in	all	regions	and	averaged	
across	 the	whole	core	 in	HGSOC,	measured	as	 log10	(counts	per	mm2).	Multivariable	analysis	was	adjusted	for	stage.		
	 	 	 	 Univariable	 Multivariable*	
(adjusted	for	stage)	
	 	 	 	 	 	 	 	 	
	 Functional	
Form	
Evaluable	
cases	
Tissue	
compartment	
HR	 p-value	 HR	 p-value	 	
CD8+	 log10	 301	 Epithelium	 0.89	 0.15	 0.83	 0.027	 	
	 log10	 202	 Stroma	 0.97	 0.74	 0.93	 0.40	 	
	 log10	 315	 Average	 0.79	 0.010	 0.72	 0.0006	 	
CD45RO+	log10	 290	 Epithelium	 0.86	 0.033	 0.85	 0.022	 	
	 log10	 196	 Stroma	 0.76	 0.001	 0.76	 0.0007	 	
	 log10	 306	 Average	 0.82	 0.006	 0.80	 0.003	 	
CD68+	 linear	 293	 Epithelium	 0.99	 0.67	 0.99	 0.43	 	
	 log10	 226	 Stroma	 0.53	 0.003	 0.44	 0.0003	 	
	 log10	 308	 Average	 0.67	 0.042	 0.62	 0.017	 	
Stage	 -	 312	 Localised	 1	 0	 1	 0	 	
	 	 	 Regional	 1.47	 0.26	 1.15	 0.25	 	
	 	 	 Distant	 3.96	 <<0.001	 5.58	 <<0.001	 	
	 	 	 Unstaged	 3.35	 <0.001	 3.34	 <<0.001	 	
	
	
Table	2.	 	Multivariable	Cox	regression	hazard	ratios	and	associated	p-values	for	a	model	with	all	
infiltrates	and	stage	and	for	a	reduced	model	with	most	significant	variables	only	(n=152).	
	 	 Multivariable		
(all	combined)	
Refined	model	
	 	 	 	 	 	
	 	 HR	 p-value	 HR	 p-value	
CD8+	 Epithelium	 0.96	 0.81	 -	 -	
	 Stroma	 1.07	 0.63	 -	 -	
CD45RO+	 Epithelium	 1.12	 0.37	 -	 -	
	 Stroma	 0.83	 0.09	 0.68	 0.11	
CD68+	 Epithelium	 1.16	 0.63	 -	 -	
	 Stroma	 0.53	 0.038	 0.88	 0.17	
Stage1	 Localised	 1	 0	 1	 0	
	 Regional	 2.00	 0.16	 2.03	 0.14	
	 Distant	 4.82	 <<0.001	 4.70	 0.0001	
	 Unstaged	 8.15	 <<0.001	 8.25	 0.0001	
	
Table	3.	Association	between	immune	infiltrate	and	genetic	alterations	in	HGSOC	tumours.	P-values	associated	with	Kruskal	Wallis	test	for	detecting	differences	in	mean	ranks	of	immune	infiltrate	in	patients	grouped	by	mutation	in	BRCA1,	BRCA2	or	not-detected,	p53	gof	or	lof	and	PTEN	high	or	low	in	HGSOC.	
	
	 	 BRCA1/	
BRCA2	
p53	GOF/LOF	 PTEN	
CD8+	 Epithelium	 0.04	 0.54	 0.67	
	 Stroma	 0.17	 0.29	 0.07	
	 Average	 0.17	 0.53	 0.84	
CD45RO+	 Epithelium	 0.20	 0.42	 0.92	
	 Stroma	 0.46	 0.84	 0.82	
	 Average	 0.10	 0.36	 0.87	
CD68+	 Epithelium	 0.43	 0.72	 0.79	
	 Stroma	 0.78	 0.85	 0.65	
	 Average	 0.68	 0.66	 0.41	
Principal	
Component	
1	 0.81	 0.80	 0.55	
2	 0.10	 0.26	 0.17	
	 3	 0.27	 0.58	 0.51	
	 4	 0.58	 0.99	 0.17	
	 5	 0.76	 0.88	 0.79	
	 6	 0.97	 0.44	 0.18	
	
